References
- Fardeau C, Champion E, Massamba N, LeHoang P. Uveitic macular edema. Eye. 2016;30:1277–1292.
- Karim R, Sykakis E, Lightman S, Fraser-Bell S. Interventions for the treatment of uveitic macular edema: a systematic review and meta-analysis. Clin Ophthalmol. 2013;7:1109–1144.
- Lowder C, Belfort R, Lightman S; et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129:545–553.
- Lam W-C, Albiani DA, Yoganathan P; et al. Real-world assessment of intravitreal dexamethasone implant (0.7 mg) in patients with macular edema: the CHROME study. Clin Ophthalmol. 2015;9:1255–1268.
- Robinson MR, Whitcup SM. Pharmacologic and clinical profile of dexamethasone intravitreal implant. Expert Rev Clin Pharmacol. 2012;5:629–647.
- Hunter RS, Lobo A-M. Dexamethasone intravitreal implant for the treatment of noninfectious uveitis. Clin Ophthalmol. 2011;5:1613–1621.
- Kuppermann BD, Blumenkranz MS, Haller JA; et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007;125:309–317.
- Haller JA, Bandello F, Belfort R Jr.; et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117:1134–1146.e3.
- Williams GA, Haller JA, Kuppermann BD; et al. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol. 2009;147:1048–1054.e2.
- Palla S, Biswas J, Nagesha CK. Efficacy of Ozurdex implant in treatment of noninfectious intermediate uveitis. Indian J Ophthalmol. 2015;63:767–770.
- Yap YC, Papathomas T, Kamal A. Results of intravitreal dexamethasone implant 0.7 mg (Ozurdex®) in non-infectious posterior uveitis. Int J Ophthalmol. 2015;8:835–838.
- Tsang AC, Virgili G, Abtahi M, Gottlieb CC. Intravitreal dexamethasone implant for the treatment of macular edema in chronic non-infectious uveitis. Ocul Immunol Inflamm. 2016;18:1–8.
- Sorkin N, Loewenstein A, Habot-Wilner Z, Goldstein M. Intravitreal dexamethasone implant in patients with persistent macular edema of variable etiologies. Ophthalmologica. 2014;232:83–91.
- Cao JH, Mulvahill M, Zhang L; et al. Dexamethasone intravitreal implant in the treatment of persistent uveitic macular edema in the absence of active inflammation. Ophthalmology. 2014;121:1871–1876.
- Khurana RN, Porco TC. Efficacy and safety of dexamethasone intravitreal implant for persistent uveitic cystoid macular edema. Retina. 2015;35:1640–1646.
- Garweg JG, Baglivo E, Freiberg FJ; et al. Response of postoperative and chronic uveitic cystoid macular edema to a dexamethasone-based intravitreal implant (Ozurdex). J Ocul Pharmacol Ther. 2016;32(7):442–450.
- Frère A, Caspers L, Makhoul D; et al. Single dexamethasone intravitreal implant in the treatment of noninfectious uveitis. J Ocul Pharmacol Ther. 2017;33(4):290–297.
- Fabiani C, Vitale A, Emmi G; et al. Systemic steroid sparing effect of intravitreal dexamethasone implant in chronic noninfectious uveitic macular edema. J Ocul Pharmacol Ther. May 30 2017. Epub ahead of print. . doi:10.1089/jop.2017.0034.
- Kumari N, Parchand S, Kaushik S, Singh R. Intractable glaucoma necessitating dexamethasone implant (Ozurdex) removal and glaucoma surgery in a child with uveitis. BMJ Case Rep. 2013. Published online. 2013 Dec 5. doi:10.1136/bcr-2013-201293.
- Khurana RN, Bansal AS, Chang LK; et al. Prospective evaluation of a sustained-release dexamethasone intravitreal implant for cystoid macular edema in quiescent uveitis. Retina.2017;37(9):1692–1699.
- Habot-Wilner Z, Sorkin N, Goldenberg D; et al. Long-term outcome of an intravitreal dexamethasone implant for the treatment of noninfectious uveitic macular edema. Ophthalmologica. 2014;232:77–82.
- Rahimy E, Khurana RN. Anterior segment migration of dexamethasone implant: risk factors, complications, and management. Curr Opin Ophthalmol. 2017;28(3):246–251.
- Lei S, Lam W-C. Efficacy and safety of dexamethasone intravitreal implant for refractory macular edema in children. Can J Ophthalmol. 2015;50:236–241.